CLINICAL TRIALS PROFILE FOR RITALIN-SR
✉ Email this page to a colleague
All Clinical Trials for RITALIN-SR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00018863 ↗ | Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2001-04-01 | This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds). |
| NCT00018863 ↗ | Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) | Completed | New York State Psychiatric Institute | Phase 3 | 2001-04-01 | This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds). |
| NCT00025779 ↗ | Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders | Completed | National Institute of Mental Health (NIMH) | N/A | 2001-10-01 | This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex). |
| NCT00129467 ↗ | Methylphenidate for Depressed Cancer Patients Receiving Palliative Care | Completed | Oregon Health and Science University | N/A | 2005-02-01 | The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI. |
| NCT00129467 ↗ | Methylphenidate for Depressed Cancer Patients Receiving Palliative Care | Completed | US Department of Veterans Affairs | N/A | 2005-02-01 | The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI. |
| NCT00129467 ↗ | Methylphenidate for Depressed Cancer Patients Receiving Palliative Care | Completed | VA Office of Research and Development | N/A | 2005-02-01 | The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI. |
| NCT00136734 ↗ | Methylphenidate Treatment for Cocaine Abuse and ADHD - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 1998-04-01 | Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RITALIN-SR
Condition Name
Clinical Trial Locations for RITALIN-SR
Trials by Country
Clinical Trial Progress for RITALIN-SR
Clinical Trial Phase
Clinical Trial Sponsors for RITALIN-SR
Sponsor Name
